Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 16/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL991458 | 0.84 | L3MBTL1 (0.45) | GRM5L3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL990882 | 0.84 | GRM5 (0.45) | GRM5L3MBTL1NPC1RAB9A | |
| SCHEMBL3432735 | 0.84 | L3MBTL1 (0.45) | GRM5L3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL991413 | 0.83 | HTR4 (0.52) | — | |
| SCHEMBL990361 | 0.83 | LMNA (0.50) | GRM5L3MBTL1NPC1RAB9A | |
| SCHEMBL990865 | 0.83 | NPC1 (0.46) | GRM5L3MBTL1NPC1RAB9A | |
| SCHEMBL990881 | 0.83 | LMNA (0.50) | GRM5L3MBTL1NPC1RAB9A | |
| SCHEMBL2815651 | 0.82 | GRM5 (0.46) | GRM5L3MBTL1NPC1RAB9A | |
| SCHEMBL990869 | 0.82 | GRM5 (0.48) | GRM5L3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL990822 | 0.82 | NPC1 (0.48) | GRM5L3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2272509-A1 | New Uses of metabotropic glutamate receptors | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-20100099682-A1 | ACETYLENE DERIVATIVES | NOVARTIS AG | 2010-04-22 | — | — | US | disclosed |
| US-7696379-B2 | Acetylene derivatives | NOVARTIS AG (CH) | 2010-04-13 | — | — | US | disclosed |
| US-20080214673-A1 | Acetylene Derivatives | NOVARTIS AG (CH) | 2008-09-04 | — | — | US | disclosed |
| EP-1877365-A1 | ACETYLENE DERIVATIVES | Novartis AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006114262-A1 | ACETYLENE DERIVATIVES | NOVARTIS AG (CH) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099682-A1 | ACETYLENE DERIVATIVES | NAT1, NAT10, F12 | GRM5 3794/4885L3MBTL1 4519/4885NPC1 677/4885 |
| US-20080214673-A1 | Acetylene Derivatives | NAT1, NAT10, F12 | GRM5 3794/4885L3MBTL1 4519/4885NPC1 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.